KOSDAQElectrical Equipment462510

Lameditech

₩1,913▼ 0.83%2026-11-18 close
Market Cap
₩16.8B
Turnover
₩30,157,101
Volume
20K
Shares out.
8.8M
PER
—
PBR
6.3×
EPS
-₩1,019
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Slump Amid Persistent Losses

Lameditech posted revenue of KRW 529 million in Q3 2026, the lowest quarter in its disclosed series, and has recorded operating losses for three straight years.

  1. 1

    Revenue reached KRW 7.19 billion in 2025, the highest of 2023–2025, while the operating loss widened to KRW 11.8 billion.

  2. 2

    Quarterly revenue ran KRW 815 million, KRW 1.13 billion and KRW 529 million across Q1–Q3 2026, with Q3 down 69.9% year on year.

  3. 3

    Because the quarterly operating loss that narrowed in Q2 widened again in Q3, the size of the Q4 loss in the 2026 annual report is the next point to check.

  4. 4

    The debt-to-equity ratio reached 199.3% at end-2025, up from 16.7% in 2024, and operating cash flow was -KRW 13.2 billion.

  5. 5

    Media reports in the first half of 2026 cited a KRW 8.3 billion convertible bond issue, and 2025 reports put expanded production capacity at about KRW 20 billion in sales terms.

02

Business structure

Lameditech develops laser-based beauty and medical devices and laser blood collection devices built on an ultra-compact, high-power laser core technology. By sales mix, the company was 81.6% beauty devices and 17.1% laser blood collection devices in 2024.

Within beauty, the PURAXEL series, which includes the professional PURAXEL-MX and the home-use PURAXEL-ME, was cited as the main driver of sales growth. PURAXEL-ME in, launched in May 2025, is a 5-in-1 home laser linked to a skincare line and an AI skin-diagnosis app, a model aimed at an integrated revenue structure.

The company sells through B2B channels, with more than 1,000 domestic aesthetic clinics and oriental medicine clinics reported in 2025, and through B2C channels including home shopping and its own online mall.

Its laser blood collection device has been listed under Korea's new medical technology designation, which the company says opens a path into the medical market.

On the medical side, the CARE BEAM excimer light device for skin disease is distributed in Japan by partner Gumje Medical, which reports a network of more than 1,000 hospitals. Production runs at a plant in Geumcheon-gu, Seoul, and the expanded capacity was reported at about KRW 20 billion in sales terms.

In regenerative medicine, the company is moving to commercialize human-derived extracellular matrix (ECM) materials. Domestic sales concentration has been pointed out as a weakness.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.8B-₩3B−168.0%
2025Q4₩1.9B-₩3.4B−183.5%
2026Q1₩800M-₩2.8B−338.4%
2026Q2₩1.1B-₩1.7B−149.3%
2026Q3₩500M-₩1.9B−365.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩2.9B-₩3.5B-₩8.3B−120.8%−97.1%31.9%
2024₩6.6B-₩9.7B-₩9.5B−146.9%−49.5%16.7%
2025₩7.2B-₩11.8B-₩11.4B−164.8%−135.0%199.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue was KRW 2.92 billion in 2023, KRW 6.58 billion in 2024 (up 125.4% year on year) and KRW 7.19 billion in 2025 (up 9.3% year on year). Revenue rose two consecutive years from 2024 through 2025, and 2025 was the largest year of 2023–2025.

Operating losses were KRW 3.53 billion, KRW 9.66 billion and KRW 11.8 billion over the same period, a three-year run of losses, and the operating margin fell from -120.8% to -146.9% and then -164.8%.

The main drivers of the wider 2024 loss were listing-related fees, advertising for B2C sales and distribution expansion, and higher sales and marketing costs. Net losses attributable to controlling shareholders were KRW 8.3 billion, KRW 9.48 billion and KRW 11.4 billion, widening in the same direction.

Operating cash flow was -KRW 3.76 billion, -KRW 9.81 billion and -KRW 13.2 billion, and in 2024 the IPO proceeds appeared as financing inflows.

At end-2025, total equity was KRW 8.42 billion, all of it attributable to controlling shareholders, and total liabilities were KRW 16.8 billion, lifting the debt-to-equity ratio from 16.7% in 2024 to 199.3%.

Quarterly revenue went from KRW 1.76 billion in Q3 2025 and KRW 1.85 billion in Q4 2025 (up 5.5% quarter on quarter) to KRW 815 million in Q1 2026 (down 56.0%), KRW 1.13 billion in Q2 (up 39.1%) and KRW 529 million in Q3 (down 53.3%).

Operating losses have run for five straight quarters from Q3 2025 to Q3 2026, narrowing from KRW 2.76 billion in Q1 2026 to KRW 1.69 billion in Q2 before widening to KRW 1.94 billion in Q3. Net losses attributable to controlling shareholders over the latest four quarters totaled KRW 8.97 billion.

In the first half of 2026, revenue fell 45.5% year on year and the operating loss was KRW 4.45 billion, and the third-quarter revenue decline was steeper than the first-half decline.

05

Industry analysis

Beauty and medical device makers depend heavily on overseas sales. Mid-sized domestic beauty and medical device companies with more than KRW 100 billion in revenue reportedly earn most of their sales abroad, with export shares of 70% or more.

Lameditech has been criticized for its domestic-heavy sales, and in 2025 it said it would widen export markets from Southeast Asia to Europe, the Middle East and South America.

On price, large laser devices used in dermatology clinics cost KRW 50–100 million, while the PURAXEL line is offered in the KRW 10 million range, placing it in a smaller, lower-priced segment.

On regulation, 2025 reports said Japan and Vietnam approvals were completed and US and European beauty-device certifications were in progress. Trade conditions are also a factor, and the company has reviewed overseas production sites in response to US reciprocal tariffs.

On demand, growing global interest in K-beauty has been cited as supporting expectations for overseas expansion.

06

Outlook

The company has said it aims to make 2026 a year of earnings recovery by strengthening its beauty and medical device business and expanding regenerative medicine. Management described 2026 as the point at which investment results start to become visible.

In products, it plans to launch the HANDS-RAGLU combined blood glucose device in Korea first and to expand overseas sales of beauty devices. In regenerative medicine, shareholders approved adding human tissue manufacturing, processing and distribution to its business purposes.

Of the KRW 8.3 billion convertible bond, KRW 2.3 billion is planned for facilities and KRW 6.0 billion for operating funds. Overseas, regular CARE BEAM exports began about a month after Japanese approval, and the partner's hospital network is expected to support profitability.

A 2025 report quoted the CEO calling the 2028 annual revenue target of KRW 50 billion achievable. Revenue for January to September 2026 totaled KRW 248 million... (see note) Cumulative revenue for January to September 2026 was KRW 2.48 billion, so the gap to that target is the next point to track.

07

Valuation

PER
—
PBR
6.3×
ROE
-128.6%
EPS
-₩1,019
BPS
₩306
Dividend per share
₩0

Net losses over the latest four quarters totaled KRW 8.97 billion, so no earnings-based multiple is calculated. The price-to-book level sits in a high-premium range, with market value far above the book value attributable to controlling shareholders at end-2025.

The company pays no dividend, so its dividend yield is below the industry average. The debt-to-equity ratio rose to 199.3% at end-2025, so debt burden relative to equity is also part of the comparison.

The company offered a profit-turnaround plan at its 2024 listing, with 2024 revenue of KRW 9.2 billion and operating profit of KRW 1 billion, but actual results diverged from that outlook, and the shortfall has been cited as a factor behind the share price weakness.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Expanded production capacity

A 2025 report said the completed expansion of production facilities allows output to roughly double. The expanded capacity was reported at about KRW 20 billion in sales terms. With revenue falling in 2026, the utilization of this capacity will show how much of this strength is translating into output.

Overseas certifications and distribution

A 2025 report said the PURAXEL ME-in obtained both US FCC and European CE LVD certifications. CARE BEAM began regular exports about a month after Japanese PMDA approval. The partner's network of more than 1,000 hospitals in Japan is cited as a distribution base.

Narrowing quarterly losses in early 2026

Operating losses narrowed from KRW 2.76 billion in Q1 2026 to KRW 1.69 billion in Q2, and net losses attributable to controlling shareholders fell from KRW 2.9 billion to KRW 829 million over the same period.

A 2025 report attributed earlier loss reduction to better cost ratios, lower component prices and process optimization.

09

Bear factors

Revenue decline

Q3 2026 revenue was KRW 529 million, down 69.9% year on year, and first-half 2026 revenue fell 45.5% year on year. All three quarterly revenue figures for 2026 came in below the KRW 1.76 billion and KRW 1.85 billion recorded in Q3 and Q4 2025.

Accumulated losses and balance-sheet strain

Operating losses have run for three straight years through 2025, and operating cash flow was -KRW 13.2 billion in 2025. Total liabilities of KRW 16.8 billion exceed total equity of KRW 8.42 billion at end-2025, a debt-to-equity ratio of 199.3%.

The 2024 third-quarter report disclosed that the largest shareholder and CEO provided a joint guarantee on borrowings.

Gap versus listing-stage forecasts

At its listing, the company projected 2024 revenue of KRW 9.2 billion and operating profit of KRW 1 billion, with a turnaround to profit. Actual 2024 revenue was KRW 6.58 billion and the operating loss was KRW 9.66 billion.

Operating losses have continued for five straight quarters through Q3 2026, and the turnaround target has not yet been reached.

10

Risk factors

Funding and dilution

The KRW 8.3 billion convertible bond carries a 0% coupon and 0% yield to maturity. If converted, the share count would rise and existing shareholdings could be diluted. With operating cash flow negative, the pace of spending and any further funding needs are key variables.

Product and market concentration

Beauty devices accounted for 81.6% of 2024 sales. Domestic-heavy sales have been identified as a weakness. Dependence on one product line and one home market leaves the company more exposed to shifts in consumer demand and distribution channels.

Approvals and overseas expansion

Overseas revenue is recognized as local approvals are completed, so timing depends on regulators. Overseas production sites were still at the candidate-selection stage in the 2025 reporting. Trade policy changes could also affect export profitability.

11

What to watch next

  1. By March 31, 2027

    Deadline for the 2026 annual report. Full-year 2026 revenue, operating loss and operating cash flow, including Q4, will be disclosed, showing whether the five-quarter loss streak extended.

  2. With the 2026 annual report, by March 31, 2027

    Actual use of the convertible bond proceeds will be compared with the plan of KRW 2.3 billion for facilities and KRW 6.0 billion for operations, which bears on financial strain and dilution.

  3. By May 15, 2027

    Deadline for the Q1 2027 quarterly report. It will show whether revenue recovers from KRW 815 million in Q1 2026 and how the operating loss of KRW 2.76 billion trends.

  4. Timing not announced

    Covers the domestic launch of the HANDS-RAGLU device and the revenue recognition timing of overseas distribution contracts. Scale can be assessed once the company discloses schedules.

12

Overall view

Lameditech's revenue rose from KRW 2.92 billion in 2023 to KRW 7.19 billion in 2025, but operating losses widened over the same period from KRW 3.53 billion to KRW 11.8 billion. Quarterly revenue in 2026 ran KRW 815 million, KRW 1.13 billion and KRW 529 million, with Q3 down 69.9% year on year.

Operating losses narrowed from KRW 2.76 billion in Q1 2026 to KRW 1.69 billion in Q2, then widened to KRW 1.94 billion in Q3. Strengths cited include expanded production capacity, US and European certifications for PURAXEL ME-in, and the start of CARE BEAM exports to Japan.

Weaknesses include falling revenue, three years of operating losses, operating cash flow of -KRW 13.2 billion and a debt-to-equity ratio of 199.3%. The next checkpoints are the full-year figures in the 2026 annual report and the use of the convertible bond proceeds. The gap between the listing-stage profit-turnaround forecast and actual results remains the central issue.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. coxnews.co.kr
  2. v.daum.net
  3. newsworker.co.kr
  4. dailyinvest.kr
  5. thebionews.net
  6. pharm.edaily.co.kr
  7. getnews.co.kr
  8. news.nate.com
  9. m.newsprime.co.kr
  10. businessreport.kr
  11. vegannews.co.kr
  12. money2.daishin.com
  13. butler.works
  14. kr.investing.com
  15. job-post.co.kr
  16. eugenefn.com
  17. medicaltimes.com
  18. view.asiae.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis